Smith & Nephew PLC 6-K, filed Feb 17, 2023
Smith & Nephew PLC (SNN)
6-K
2023-02-17
For: 2023-02-17
View Original
Added on
April 07, 2026
About this 6-K
Smith & Nephew PLC filed this 6-K on February 17, 2023.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
February 17, 2023
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew announces Rupert Soames as Chair
Designate
17 February 2023
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
company (the
Company), is pleased to announce that Rupert Soames OBE will
succeed Roberto Quarta as Chair of the Company. Mr Quarta has
reached the end of his tenure and will retire as Chair and
Non-Executive Director in 2023.
Mr Soames will be appointed as an Independent Non-Executive
Director at the Company's Annual General Meeting on 26 April 2023,
subject to shareholder approval, and will succeed Mr Quarta as
Chair with effect from 15 September 2023. Mr Quarta has agreed to
continue as Chair to ensure a smooth transition and will put
himself forward for re-election as a Non-Executive Director on 26
April 2023 on this basis.
Mr Soames has extensive global leadership experience in both
executive and non-executive roles. Most recently he served as Chief
Executive Officer of Serco Group plc, the global outsourced
services provider, between 2014 and 2022 where he led the
successful turnaround. He was Chief Executive of Aggreko plc, the
support services company (2003-2014) and also served as a
Non-Executive Independent Director at both DS Smith, the
sustainable packaging business (2019-2022) and support services
company Electrocomponents plc (2007-2016) (now RS Group). On
joining the Board, Mr Soames will be appointed to the Nomination
& Governance Committee and the Remuneration
Committee.
Marc Owen, Senior Independent Director, who along with the
Nomination & Governance Committee led the Chair search process,
commented:
"The Board conducted an extensive search for a new Chair and we are
delighted to welcome Rupert to the Board. We believe that Rupert's
extensive track record of value creation in global companies and
deep understanding of corporate governance will help Deepak Nath
and his team deliver on their existing plans to grow
the business and to improve its operational performance. I would
like to thank Roberto for his unwavering commitment and support to
the Board and for his contribution and service to the Company
during his tenure."
Rupert Soames said:
"Smith+Nephew is a leader in the medical technology sector with a
167-year history of supporting patients to return to health. I am
honoured to be the next Chair of the Board, and look forward to
working with Deepak, the Smith+Nephew organisation and the Board to
deliver on Smith+Nephew's great potential."
No further disclosure obligations arise under paragraphs (1) to (6)
of LR 9.6.13 R of the UK Listing Authority's Listing Rules in
respect of this appointment.
Enquiries
|
Investors / Analysts
Andrew
Swift
Smith+Nephew
|
+44 (0)
1923 477433
|
|
Media
Charles
Reynolds
Smith+Nephew
|
+44 (0)
1923 477314
|
|
Susan
Gilchrist / Ayesha Bharmal
Brunswick
|
+44 (0)
20 7404 5959
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Sports Medicine & ENT and Advanced
Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in
2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer
to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID; economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID); competition
for qualified personnel; strategic actions, including acquisitions
and dispositions, our success in performing due diligence, valuing
and integrating acquired businesses; disruption that may result
from transactions or other changes we make in our business plans or
organisation to adapt to market developments; and numerous other
matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with
the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended,
including Smith+Nephew's most recent annual report on Form 20-F,
for a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark
of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: February
17, 2023
By: /s/
Helen Barraclough
-----------------
Helen
Barraclough
Company
Secretary